These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28095918)

  • 21. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1376-83. PubMed ID: 16569855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
    Lepak AJ; Zhao M; Liu Q; Wang P; Wang Y; Bader JC; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacteriological efficacy of nafcillin and vancomycin alone or combined with rifampicin or amikacin in experimental meningitis due to methicillin-susceptible or -resistant Staphylococcus aureus.
    Sato K; Lin TY; Weintrub L; Olsen K; McCracken GH
    Jpn J Antibiot; 1985 Aug; 38(8):2155-62. PubMed ID: 3852897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and tolerability of BAY41-6551 in subjects with chronic kidney disease.
    Stass H; Corkery K; Gribben D; Eldon MA
    J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):191-9. PubMed ID: 21599533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model.
    So W; Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4956-61. PubMed ID: 26055376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia.
    Niederman MS; Chastre J; Corkery K; Fink JB; Luyt CE; García MS
    Intensive Care Med; 2012 Feb; 38(2):263-71. PubMed ID: 22147112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals.
    Housman ST; Sutherland CA; Nicolau DP
    Int J Antimicrob Agents; 2014 Sep; 44(3):235-41. PubMed ID: 25052866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic
    Heffernan AJ; Sime FB; Sarovich DS; Neely M; Guerra-Valero Y; Naicker S; Cottrell K; Harris P; Andrews KT; Ellwood D; Wallis SC; Lipman J; Grimwood K; Roberts JA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32660986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus.
    Tsuji BT; Yang JC; Forrest A; Kelchlin PA; Smith PF
    J Antimicrob Chemother; 2008 Jul; 62(1):156-60. PubMed ID: 18400804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Noel A; Tomaselli S; Elliott H; Bowker K
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1436-42. PubMed ID: 21263054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nebulized Amikacin and Fosfomycin for Severe Pseudomonas aeruginosa Pneumonia: An Experimental Study.
    Li Bassi G; Motos A; Fernandez-Barat L; Aguilera Xiol E; Chiurazzi C; Senussi T; Saco MA; Fuster C; Carbonara M; Bobi J; Amaro R; De Rosa F; Comaru T; Yang H; Ranzani OT; Marti JD; Rinaudo M; Comino Trinidad O; Rigol M; Bringué J; Ramirez J; Nicolau DP; Pelosi P; Antonelli M; Blasi F; Artigas A; Montgomery AB; Torres A
    Crit Care Med; 2019 Jun; 47(6):e470-e477. PubMed ID: 30882478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy of human-simulated epithelial lining fluid exposures of tedizolid, linezolid and vancomycin in neutropenic and immunocompetent murine models of staphylococcal pneumonia.
    Kidd JM; Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2019 Apr; 74(4):970-977. PubMed ID: 30561650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
    Stein GE; Wells EM
    Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Blondeau JM; Blondeau LD; Fitch SD
    J Chemother; 2024 Sep; 36(5):389-397. PubMed ID: 38339845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical laboratory approach to evaluate efficacy of amikacin. Reevaluation of in vitro MIC break points in disc susceptibility test].
    Uete G; Matsuo K; Uete T
    Jpn J Antibiot; 1992 May; 45(5):489-501. PubMed ID: 1512934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Zazo H; Martín-Suárez A; Lanao JM
    Int J Antimicrob Agents; 2013 Aug; 42(2):155-60. PubMed ID: 23756322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
    LaPlante KL; Rybak MJ
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2004)].
    Goto H; Takeda H; Kawai S; Watanabe T; Okazaki M; Shimada K; Nakano K; Yokouchi H; Ikemoto H; Mori T; Igari J; Oguri T; Yamamoto M; Inoue H; Nakadate T; Suwabe A; Ashino Y; Gejyo F; Okada M; Aoki N; Kitamura N; Suzuki Y; Karasawa Y; Kudo K; Kobayashi N; Tanaka T; Sumitomo M; Matsushima T; Oka M; Niki Y; Suga M; Tosaka M; Kohno S; Hirakata Y; Kondou A; Matsuda J; Nakano M; Nasu M; Hiramatsu K; Oikawa S
    Jpn J Antibiot; 2006 Oct; 59(5):323-54. PubMed ID: 17180803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.
    Lepak AJ; Marchillo K; Craig WA; Andes DR
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1258-64. PubMed ID: 25512404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.
    Kresken M; Körber-Irrgang B; Läuffer J; Decker-Burgard S; Davies T
    Int J Antimicrob Agents; 2011 Jul; 38(1):70-5. PubMed ID: 21514795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.